First Time Loading...

Emergent BioSolutions Inc
NYSE:EBS

Watchlist Manager
Emergent BioSolutions Inc Logo
Emergent BioSolutions Inc
NYSE:EBS
Watchlist
Price: 1.86 USD -2.11% Market Closed
Updated: Apr 19, 2024
Section:
 

Wall Street
Price Targets

EBS Price Targets Summary
Emergent BioSolutions Inc

Wall Street analysts forecast EBS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EBS is 5.1 USD with a low forecast of 5.05 USD and a high forecast of 5.25 USD.

EBS Lowest Forecast
Wall Street Target
5.05 USD
172% Upside
EBS Average Forecast
Wall Street Target
5.1 USD
174% Upside
EBS Highest Forecast
Wall Street Target
5.25 USD
182% Upside
Lowest
Price Target
5.05 USD
172% Upside
Average
Price Target
5.1 USD
174% Upside
Highest
Price Target
5.25 USD
182% Upside
Emergent BioSolutions Inc Competitors:
Price Targets
KDNY
Chinook Therapeutics Inc
1% Downside
BIOG B
Biogaia AB
30% Upside
ZYME
Zymeworks Inc
72% Upside
A
ALACT
Acticor Biotech SA
183% Upside
KDNY
Chinook Therapeutics Inc
1% Downside
BIOG B
Biogaia AB
30% Upside
ZYME
Zymeworks Inc
72% Upside
A
ALACT
Acticor Biotech SA
183% Upside
REGN
Regeneron Pharmaceuticals Inc
20% Upside
9995
RemeGen Co Ltd
65% Upside
6160
Beigene Ltd
74% Upside
AVCT
Avacta Group PLC
96% Upside

Revenue
Forecast

Revenue Estimate
Emergent BioSolutions Inc

For the last 8 years the compound annual growth rate for Emergent BioSolutions Inc's revenue is 10%. The projected CAGR for the next 3 years is -8%.

10%
Past Growth
-8%
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Emergent BioSolutions Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-11%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Emergent BioSolutions Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-21%
Average Miss
What are analyst estimates?

See Also

Summary
EBS intrinsic value, competitors valuation, and company profile.
DCF Valuation
EBS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
EBS stock valuation using valuation multiples.
Wall Street Estimates
EBS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
EBS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is EBS's stock price target?
Price Target
5.1 USD

According to Wall Street analysts, the average 1-year price target for EBS is 5.1 USD with a low forecast of 5.05 USD and a high forecast of 5.25 USD.

What is Emergent BioSolutions Inc's Revenue forecast?
Projected CAGR
-8%

For the last 8 years the compound annual growth rate for Emergent BioSolutions Inc's revenue is 10%. The projected CAGR for the next 3 years is -8%.

ALPHA SPREAD
Join more than 129,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.